Hansoh Pharmaceutical Group Company Limited
http://www.hansoh.cn/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hansoh Pharmaceutical Group Company Limited
GSK Boosts Its Infectious Disease Portfolio With Brexafemme License
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Chinese Biotech Financing Rebounds But Mega Deals Missing
Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Fewer Biotech-Pharma M&As But Tie-ups Indicate New China Trends
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Distributors
- Pharmaceuticals
- Contract Manufacturing Organization
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- Jiangsu Hansoh Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice